Serum amyloid A in Alzheimer's disease brain is predominantly localized to myelin sheaths and axonal membrane

Amyloid

Volumn 7, Issue 2, 2000, Pages 105-110

  Chung, Tzu Feng ^a   Sipe, Jean D ^b   McKee, Ann ^a,c   Fine, Richard E ^a,c   Schreiber, Barbara M ^a   Liang, Jun Shan ^a   Johnson, Robin J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute phase protein; Alzheimer's disease; Immunohistochemistry; Inflammation; Myelin; Serum amyloid A

Indexed keywords

ACUTE PHASE PROTEIN; APOLIPOPROTEIN; SERUM AMYLOID A;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LEWY BODY; LIPOGENESIS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE DEGENERATION; NERVE FIBER MEMBRANE; PARKINSON DISEASE; PATHOGENESIS; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0034039716     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120009146246     Document Type: Article

References (22)

1. Fazekas F., Schmidt R. and Scheltens P. (1998). Pathophysiologic mechanisms in the development of age-related white matter changes of the brain. Dement Geriatr Cogn Disord 9 (Suppl. 1), 2-5
2. Yankner B.A. (1996). Mechanisms of neuronal degeneration in Alzheimer's Disease. Neuron 16, 921-932
3. Sipe J. (1994). Amyloidosis. Crit Rev Clin Lab Sci 31, 325-354
4. Kumon Y., Sipe J.D., Brinckerhoff C.E. and Schreiber B.M. (1997). Regulation of extrahepatic apolipoprotein serum amyloid A (apoSAA) gene expression by interleukin-1α alone: Synthesis and secretion of apoSAA by cultured aortic smooth muscle cells. Scand J Immunol 46, 284-292
5. Hardardottir I., Sipe J.D., Moser A.H., Fielding C.J., Feingold K.R. and Grunfeld C. (1997). LPS and cytokines regulate extrahepatic mRNA levels of apolipoproteins during the acute phase response in Syrian hamsters. Biochim Biophys Acta 1344, 210-220
6. Afagh A, Cummings BJ, Cribbs DH, Cotman CW and Tenner AJ (1996). Localization and cell association of C1q in Alzheimer's Disease. Exp Neurol 138, 22-32
7. McGeer PL and McGeer EG (1995). The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21, 195-218
8. Rogers J (1995). Inflammation as a pathogenic mechanism in Alzheimer's disease. Arzneim-Forsch/Drug Res 45, 39-44
9. Liang J-s, Sloane JA, Wells J, Abraham CR, Fine RE and Sipe JD (1997). Evidence for local production of the acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Neurosci Lett 225, 73-76
10. Godenir ML, Jeenah MS, Coetzee GA, van der Westhuysen DR and de Beer FC (1985). Standardization of the quantitation of serum amyloid A protein (SAA) in human serum. J Immunol Methods 83, 217-225
11. Wood PL (1998). Role of CNS macrophages in neurodegeneration. In Wood, PL (ed.) Neuroinflammation: Mechanisms and Management, pp. 1-59. (Humana Press, Totowa, New Jersey)
12. Griffin WST, Sheng JG, Roberts GW and Mrak RE (1995). Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 54, 276-281
13. Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y and Quirion R (1993). Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1β or IL-1RA but increases in the associated acute phase proteins IL-6, a2-macroglobulin and C-reactive protein. Brain Res 625, 245-252
14. Morrison JH, Lewis DA, Campbell MJ, Huntley GW, Benson DL and Bouras C (1987). A monoclonal antibody to non-phosphorylated neurofilament protein marks the vulnerable cortical neurons in Alzheimer's disease. Brain Res 416, 331-336
15. Liang J-s, Schreiber BM, Salmona M, Phillip G, Gonnerman WA, de Beer FC and Sipe JD (1996). The amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle cells and Hep G2 cells. J Lipid Res 37, 2109-2116
16. Schreiber BM, Veverbrants M, Fine RE, Blusztajn JK, Salmona M, Patel A and Sipe JD (1999). Apolipoprotein serum amyloid A (SAA) down regulates smooth muscle cell lipid biosynthesis. Biochem J, in press
17. Blusztajn JK, Lopez Gonzalez-Coviella I, Logue M, Growdon JH and Wurtman RJ (1990). Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients. Brain Res 536, 240-244
18. Nitsch RM, Blusztajn JK, Pittas AJ, Slack BE, Growdon JH and Wurtman RJ (1992). Evidence for a membrane defect in Alzheimer's disease brain. Proc Natl Acad Sci USA 89, 1671-1675
19. Gottfries CG, Karlsson I and Svennerholm L (1996). Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. Int Psychogeriatr 8, 365-372
20. Svennerholm L and Gottfries CG (1994). Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem 62, 1039-1047
21. Liang J-s, Stone PJ and Sipe JD (1995). Serum Amyloid A (ApoSAAp) catabolism: Dual Cellular mechanisms and attenuation by lipids and lipoprotein. FASEB J 9, A1043
22. Ristori G, Laurenti F, Stacchini P, Gasperini C, Buttinelli C, Pozzilli C and Salvetti M (1998). Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis. J Neuroimmunol 88, 9-12